Drugs Containing Excipient (Inactive Ingredient) GLYCERYL STEARATE/PEG-100 STEARATE

Generic drugs containing GLYCERYL STEARATE/PEG-100 STEARATE excipient

Company	Ingredient	NDC	Excipient
Encube Ethicals Inc	clobetasol propionate cream usp, 0.05%	21922-016	GLYCERYL STEARATE/PEG-100 STEARATE
A-S Medication Solutions	clobetasol propionate usp, 0.05%	50090-5979	GLYCERYL STEARATE/PEG-100 STEARATE
A-S Medication Solutions	clobetasol propionate usp, 0.05%	50090-7392	GLYCERYL STEARATE/PEG-100 STEARATE
NuCare PharmaceuticalsInc	clobetasol propionate cream	68071-1596	GLYCERYL STEARATE/PEG-100 STEARATE
NuCare PharmaceuticalsInc	clobetasol propionate cream usp, 0.05%	68071-2489	GLYCERYL STEARATE/PEG-100 STEARATE

Glyceryl Stearate/PEG-100 Stearate Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Glyceryl stearate/PEG-100 stearate is an established nonionic emulsifying excipient used primarily in topical creams, lotions, ointments, emulsions, and selected oral or personal-care formulations. Its commercial profile is driven by formulation utility, regulatory acceptance, supply reliability, and demand for stable oil-in-water systems rather than by exclusivity rights.

The ingredient does not have a publicly reported standalone market revenue line. Suppliers generally include it within broader emulsifiers, specialty chemicals, pharmaceutical excipients, cosmetic ingredients, or personal-care portfolios. A defensible financial assessment therefore relies on end-market demand, pricing behavior, supplier capacity, and product substitution rather than a verified global revenue figure for the specific excipient.

What is glyceryl stearate/PEG-100 stearate?

Glyceryl stearate/PEG-100 stearate is a nonionic emulsifier composed of glyceryl stearate and polyethylene glycol 100 stearate. It is commonly supplied as a waxy solid or pelletized material and is used to form and stabilize oil-in-water emulsions.

The ingredient provides several formulation functions:

• Primary or secondary emulsification
• Texture modification
• Emulsion stabilization
• Skin-feel improvement
• Viscosity contribution
• Compatibility with oils, waxes, fatty alcohols, and aqueous phases

It is often used with co-emulsifiers such as cetostearyl alcohol, stearyl alcohol, glyceryl stearate, polysorbates, sorbitan esters, or polymeric rheology modifiers. Product performance depends on hydrophilic-lipophilic balance, fatty-acid composition, ethoxylation profile, particle size, melting behavior, and manufacturing consistency.

Commercial products include materials marketed under names such as Arlacel 165 and Cutina 165, although formulation grade, regional availability, and current ownership or distribution arrangements must be verified against supplier documentation. The INCI designation is generally "Glyceryl Stearate (and) PEG-100 Stearate," while pharmaceutical labeling may use compendial or supplier-specific nomenclature.

What are the principal applications of glyceryl stearate/PEG-100 stearate?

The largest demand base is topical and personal-care formulation.

Pharmaceutical applications

In pharmaceutical products, the excipient is used in:

• Dermatological creams
• Emulsified ointments
• Topical gels and lotions
• Transdermal or dermal delivery systems
• Barrier creams
• Medicated cosmetic products
• Selected oral emulsions and suspensions

The principal commercial value is formulation enablement. The excipient can support a stable, cosmetically acceptable product without relying on ionic surfactants that may create compatibility or irritation issues.

Topical pharmaceuticals are particularly relevant because generic and branded products often require robust emulsion systems. A formulation change may trigger comparative studies, stability work, preservative assessment, container-closure testing, and regulatory variation filings. That switching cost can protect incumbent excipient suppliers even when the underlying material is not patent-protected.

Cosmetics and personal care

Personal-care products account for broad volume demand. Uses include:

• Moisturizers
• Facial and body creams
• Sunscreens
• Cleansers
• Hair conditioners
• After-sun products
• Baby-care products
• Color cosmetics

Personal-care demand is more price-sensitive than pharmaceutical demand. Cosmetic manufacturers can often qualify alternative emulsifiers, but sensory attributes, processing conditions, and consumer acceptance limit immediate substitution.

Industrial and specialty formulations

Smaller applications include agricultural formulations, industrial emulsions, and specialty coatings. These markets are generally less dependent on pharmaceutical-grade documentation and may purchase technical or cosmetic grades at lower prices.

How large is the glyceryl stearate/PEG-100 stearate market?

No major public supplier reports glyceryl stearate/PEG-100 stearate as a separately audited revenue category. Published market studies generally aggregate it into broader categories such as emulsifiers, cosmetic ingredients, fatty-acid derivatives, specialty surfactants, or pharmaceutical excipients.

This creates three financial conclusions:

1. The ingredient is a niche product within much larger emulsifier and excipient markets.
2. Public market-size estimates for the specific ingredient are often model-based rather than supplier-reported.
3. Revenue growth should be assessed through application growth and supplier performance, not through unverified standalone market forecasts.

The addressable market is supported by three structural factors: continued use of semisolid dosage forms, growth in dermatology and self-care, and demand for multifunctional nonionic emulsifiers. Growth is constrained by mature technology, broad substitution options, and limited differentiation between qualified grades.

What is driving demand growth?

Dermatology and topical generics

Topical generic drugs require stable, reproducible formulations that meet pharmaceutical quality and performance requirements. Growth in dermatology, wound care, antifungal products, corticosteroid creams, and consumer health products supports demand for emulsifying excipients.

The strongest demand is likely to come from products requiring oil-in-water creams with established processing protocols. Once a product is approved and commercialized, the excipient may remain embedded in the formulation for years because replacement can affect viscosity, droplet size, preservative distribution, release, and skin feel.

Personal-care premiumization

Premium moisturizers and treatment products use structured emulsions and demand consistent sensory performance. Glyceryl stearate/PEG-100 stearate can benefit from this trend, although it competes with natural emulsifiers, lamellar systems, polyglycerol esters, and newer multifunctional ingredients.

Manufacturing simplification

Formulators often prefer self-emulsifying blends that reduce process complexity. A pre-balanced glyceryl stearate/PEG-100 stearate product can reduce development time compared with assembling multiple individual surfactants.

Regional pharmaceutical manufacturing

India, China, Southeast Asia, Latin America, and the Middle East have expanding generic and topical manufacturing bases. Local production growth supports excipient consumption, but customers in these regions are also more likely to pursue dual sourcing and lower-cost technical alternatives.

How does pricing work for this excipient?

Pricing is determined by grade, purity, documentation, packaging, order size, region, and supply contract terms. Pharmaceutical and cosmetic grades do not have equivalent commercial pricing.

Main price variables

• Pharmaceutical versus cosmetic or technical grade
• Compendial compliance
• GMP manufacturing and audit history
• Residual ethylene oxide and ethylene glycol controls
• Microbiological specifications
• Lot-to-lot consistency
• Regulatory support package
• Regional warehousing
• Minimum order quantity
• Container size
• Supply-contract duration

Feedstock economics also matter. The product depends on stearic and palmitic acid fractions, glycerol, ethylene oxide, energy, packaging, and logistics. Ethylene oxide costs and regulatory controls can affect PEG ester economics. Fatty-acid prices are linked to vegetable oils, animal fats, oleochemical capacity, and regional supply balances.

The market generally has moderate price competition. A pharmaceutical customer may pay a premium for qualified supply, but that premium is limited by the availability of alternative nonionic emulsifiers.

Who are the main suppliers?

The competitive landscape includes global specialty-chemical companies, oleochemical manufacturers, cosmetic-ingredient distributors, and regional excipient suppliers.

Relevant supplier groups include:

Supplier group	Typical competitive advantage
Global specialty-chemical companies	Regulatory infrastructure, global distribution, technical support
Oleochemical producers	Feedstock integration and cost control
Pharmaceutical excipient suppliers	GMP documentation, audits, compendial support
Cosmetic ingredient manufacturers	Sensory expertise and formulation support
Regional distributors	Local inventory, smaller order fulfillment, customer access
Contract manufacturers	Private-label production and customized specifications

Croda and BASF have historically marketed widely recognized emulsifier products in this class, including Arlacel and Cutina product families. Product ownership, manufacturing location, and distributor arrangements can change, so procurement teams should verify current technical data sheets, certificates of analysis, regulatory statements, and supply contracts before treating a named brand as an available source.

Supplier differentiation is strongest in documentation, batch consistency, technical support, and regional inventory. The base chemistry is mature and relatively difficult to protect through broad composition patents.

What regulatory status does glyceryl stearate/PEG-100 stearate have?

Glyceryl stearate and PEG-based stearate esters are established excipient materials with use histories in pharmaceutical and cosmetic products. Regulatory treatment depends on the precise chemical description, grade, route of administration, concentration, and jurisdiction.

United States

The U.S. Food and Drug Administration’s Inactive Ingredient Database is the principal public reference for excipient precedent in approved drug products. An IID listing does not constitute blanket approval for every route, strength, dosage form, or product. Sponsors must confirm the relevant ingredient name, route, dosage form, and maximum potency against the current database. [1]

For topical products, the regulatory assessment usually focuses on:

• Identity and composition
• Impurities and residual solvents
• Microbiological quality
• Stability
• Skin tolerance
• Compatibility with the active ingredient
• Manufacturing controls
• Container-closure interaction

The ingredient may also be subject to applicable USP-NF monographs or supplier specifications. The exact compendial status should be checked against the current United States Pharmacopeia-National Formulary edition. [2]

European Union

European pharmaceutical sponsors typically evaluate excipient quality under EU pharmaceutical legislation, European Pharmacopoeia requirements where applicable, and the excipient risk framework applied by the European Medicines Agency and national authorities. The regulatory file must establish consistent quality and appropriate use in the proposed product. [3]

Cosmetics

In the European Union, the ingredient is assessed under the Cosmetics Regulation and appears under the relevant INCI nomenclature. Cosmetic manufacturers remain responsible for safety assessment, impurity control, product information files, and compliance with restrictions applicable to the finished product. [4]

What manufacturing and intellectual-property barriers affect supply?

The main barriers are manufacturing know-how, quality control, regulatory qualification, and supply-chain reliability. Broad patent exclusivity is generally not the primary barrier.

Manufacturing requirements

Production typically involves esterification or transesterification of fatty-acid and glycerol components, followed by ethoxylation or incorporation of PEG-derived functionality, purification, finishing, and solidification. Critical controls include:

• Ethoxylation degree
• Acid value
• Saponification value
• Hydroxyl value
• Moisture
• Free polyethylene glycol
• Free fatty acids
• Residual ethylene oxide
• Residual ethylene glycol
• Dioxane and related impurities
• Color and odor
• Melting range
• Microbial quality

The process requires controlled handling of ethylene oxide or PEG-derived intermediates. This creates equipment, safety, environmental, and quality-system barriers.

Patent position

The underlying excipient chemistry is mature. A broad, enforceable composition patent covering ordinary glyceryl stearate/PEG-100 stearate is unlikely to be the main commercial constraint. Potentially relevant rights may instead involve:

• Specific manufacturing processes
• Narrow impurity profiles
• Particle or pellet morphology
• Customized blends
• Pharmaceutical formulations
• Delivery systems
• Use in a specific dosage form

Patent searches should be conducted by chemical structure, trade name, supplier, formulation, and jurisdiction. A search limited to the common ingredient name may miss patents claiming a blend, process, or finished product.

How strong is the competitive position of this excipient?

The product has a durable but not highly protected market position.

Factor	Assessment	Commercial effect
Technical maturity	High	Low development risk, but limited differentiation
Supplier substitutability	Moderate to high	Caps pricing power
Pharmaceutical switching cost	Moderate	Supports incumbent supply after qualification
Cosmetic switching cost	Low to moderate	Customers can reformulate more readily
Regulatory familiarity	High	Supports adoption
Patent protection	Generally limited	Does not block competing production
Feedstock exposure	Moderate	Margins may fluctuate
Documentation requirements	High for pharma	Favors established suppliers
Regional supply concentration	Variable	Can create temporary shortages

The strongest competitive position belongs to suppliers with validated pharmaceutical grades, global quality systems, reliable inventory, and technical support. A low-cost producer without regulatory documentation may compete effectively in cosmetics but struggle to displace a qualified pharmaceutical supplier.

What generic-entry risks exist for products using this excipient?

Glyceryl stearate/PEG-100 stearate itself does not create a conventional generic-entry barrier. It is an excipient, not an active pharmaceutical ingredient, and it normally does not provide market exclusivity.

Its strategic importance is indirect. A branded or generic drug product may rely on the excipient for:

• Emulsion stability
• Active-ingredient release
• Preservative distribution
• Viscosity
• Skin penetration
• Patient acceptability
• Shelf life

A competing manufacturer can usually use the same excipient or an alternative, subject to formulation development and regulatory requirements. The key risks are therefore product-specific:

1. The formulation may be difficult to reproduce.
2. The supplier may be single-sourced.
3. A change in grade may alter product performance.
4. A formulation patent may claim the excipient combination.
5. A process patent may cover the finished dosage form.
6. Regulatory filing requirements may delay substitution.

The excipient can raise development costs without independently preventing generic entry.

What is the financial trajectory for suppliers?

The likely financial trajectory is steady, application-led growth with limited standalone margin expansion. Revenue should track the broader pharmaceutical, dermatology, cosmetic, and specialty-emulsifier markets.

Near-term outlook

Near-term performance is likely to reflect:

• Raw-material volatility
• Energy and freight costs
• Inventory normalization
• Demand from topical generics
• Cosmetic volume recovery
• Customer destocking
• Regional capacity additions

Suppliers with integrated oleochemical feedstocks may have better margin protection than distributors or manufacturers dependent on purchased fatty acids.

Medium-term outlook

Medium-term growth should be supported by:

• More topical and dermatology products
• Expansion of generic manufacturing
• Higher demand for multifunctional emulsifiers
• Growth in premium skin-care products
• Continued use of semisolid dosage forms

Margin pressure will come from:

• Alternative emulsifier systems
• Private-label competition
• Customer dual sourcing
• Lower-cost Asian production
• Substitution with glyceryl stearate, polysorbates, sorbitan esters, polyglycerol esters, and polymeric emulsifiers

Revenue exposure

Because companies do not generally disclose sales by this individual excipient, revenue exposure is best evaluated through portfolio concentration:

• A supplier focused on cosmetic emulsifiers has higher volume exposure but lower switching costs.
• A pharmaceutical-grade supplier has lower volume and stronger documentation-related pricing.
• A vertically integrated oleochemical company may have better cost control.
• A distributor has lower manufacturing risk but thinner structural margins.

How does glyceryl stearate/PEG-100 stearate compare with competing emulsifiers?

Excipient class	Main advantage	Main limitation
Glyceryl stearate/PEG-100 stearate	Familiar, effective oil-in-water emulsifier	Ethoxylated chemistry and substitution availability
Glyceryl stearate alone	Strong texture and emolliency	Often needs a co-emulsifier
Polysorbates	Broad pharmaceutical use and water compatibility	Oxidation and impurity concerns in some applications
Sorbitan esters	Useful lipophilic emulsification	Often require combination systems
Cetearyl glucoside systems	Natural-positioning and mild sensory profile	May require different processing and cost structure
Polyglycerol esters	Formulation flexibility and non-ethoxylated positioning	Less universal regulatory and formulation familiarity
Phospholipid emulsifiers	Functional and marketing differentiation	Higher cost and greater oxidation sensitivity
Acrylic or polymeric emulsifiers	High efficiency at low use levels	Different processing and electrolyte sensitivity

Glyceryl stearate/PEG-100 stearate remains competitive where formulators prioritize known processing behavior, broad supplier availability, and established sensory performance.

What should investors and procurement teams monitor?

The most relevant indicators are operational rather than patent-driven:

• Supplier qualification status
• Number of approved manufacturing sites
• Dual-source availability
• Current compendial and regulatory documentation
• PEG-related impurity controls
• Fatty-acid feedstock prices
• Ethylene oxide supply and compliance costs
• Regional lead times
• Customer concentration
• Cosmetic versus pharmaceutical sales mix
• Product-specific formulation dependence
• Availability of non-ethoxylated alternatives

A supplier with one manufacturing site, limited regulatory support, and high dependence on imported feedstock has higher interruption risk. A supplier with multiple sites, pharmaceutical-grade documentation, and local inventory has stronger commercial resilience.

Key Takeaways

• Glyceryl stearate/PEG-100 stearate is a mature nonionic emulsifier used mainly in topical pharmaceuticals, cosmetics, and personal-care products.
• No reliable public standalone revenue series exists for the specific excipient.
• Financial performance is tied to broader emulsifier, dermatology, topical-generic, and skin-care demand.
• The chemistry has limited broad patent protection; manufacturing quality and regulatory qualification are more important barriers.
• Pharmaceutical customers pay for documentation, consistency, and supply reliability, while cosmetic customers are more price-sensitive.
• Substitution is technically possible but can require formulation redevelopment and regulatory work.
• The strongest suppliers combine oleochemical or specialty-chemical manufacturing with GMP systems, global distribution, and technical support.
• Long-term growth is likely to be steady rather than explosive, with margin pressure from alternative emulsifiers and regional low-cost suppliers.

FAQs

Is glyceryl stearate/PEG-100 stearate a pharmaceutical excipient?

Yes. It is used as an emulsifying and consistency-modifying excipient in topical and other semisolid formulations, subject to applicable regulatory and compendial requirements.

Is glyceryl stearate/PEG-100 stearate covered by a patent?

The mature base chemistry is generally not dependent on a broad, active composition patent. Specific manufacturing processes, blends, formulations, or delivery systems may have separate patent claims.

Can PEG-100 stearate be replaced in a cream formulation?

Yes, but replacement may change emulsion stability, viscosity, release, preservative behavior, sensory properties, and shelf life. Pharmaceutical products may require comparative development and regulatory assessment.

What is the difference between Arlacel 165 and generic glyceryl stearate/PEG-100 stearate?

Arlacel 165 is a commercial product designation. Generic materials may have the same nominal ingredient description but differ in fatty-acid profile, processing, impurity limits, particle form, documentation, and performance.

Is glyceryl stearate/PEG-100 stearate a high-margin excipient?

It can generate attractive margins in pharmaceutical-grade and technically supported applications, but the base product is relatively substitutable. Margins depend on quality systems, feedstock integration, customer qualification, and supply reliability.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org

3. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu

4. European Parliament and Council of the European Union. (2009). Regulation (EC) No 1223/2009 on cosmetic products. https://eur-lex.europa.eu

5. Croda International Plc. (n.d.). Arlacel and pharmaceutical excipient product information. https://www.croda.com

6. BASF SE. (n.d.). Cutina emulsifier product information. https://pharma.basf.com